1.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
2.	LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.131, 2011-000392-14, NCT01345669
3.	CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000727295, NCCTG-N11C5, N11C5, NCT01545687
4.	The Quarterback Trial Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 12-1050, HS 12-00359, IF 1403412, NCT01706939
5.	Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
6.	Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
7.	Study of PX-866 and Docetaxel in Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-866-002, NCT01204099
8.	A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG 254, NCT01744340
9.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
10.	A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
11.	A Study in Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13420, I4E-MC-JXBB, NCT01063075
12.	Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01162, ENT0025, SUMC-ENT 0025, 8209, NCT00841997, NCT00896181
13.	Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck Phase: Phase II Type: Treatment Status: Active Age: 18 to 89 Sponsor: Other Protocol IDs: 10-069-B, NCT01133678
14.	Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0885, NCT01154920
15.	Minocycline in Oropharynx Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 2010-0096, NCT01173692
16.	Pilot Study for Locally Advanced Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-039, UPCI 09-039, NCT01262859
17.	Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 20080645, NCT01305772
18.	Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DCA 2010, NCT01386632
19.	Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ENT0033, SU-08222011-8290, 22329, NCI-2011-03271, NCT01437449
20.	Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: any age Sponsor: Other Protocol IDs: 11-130, NCT01498484
21.	Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NSLIJ0844, NCT01525927
22.	Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CTRC 11-36, HSC20120002H, NCT01588431
23.	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01640, 12-1359, N01CM00071, NCT01696955
24.	A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 136191, NCT01820312
25.	Vaccine Therapy in Treating Patients With Head and Neck Cancer Phase: Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000515081, PCI-03-156, PCI-0507062, NCT00404339